Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

M.M. Eggermont, Alexander; Kiciński, Michal; U. Blank, Christian; Mandalà, Mario; V. Long, Georgina; Atkinson, Victoria; Dalle, Stéphane; Haydon, Andrew; Khattak, Adnan; S. Carlino, Matteo; Sandhu, Shahneen; Larkin, James; Puig, Susana; A. Ascierto, Paolo; Rutkowski, Piotr; Schadendorf, Dirk; H.T. Koornstra, Rutger; F. Hernandez‐Aya, Leonel; Maria Di Giacomo, Anna; Johannes Maria van den Eertwegh, Alfonsus; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; Lorigan, Paul; Krepler, Clemens; Ibrahim, Nageatte; Marréaud, Sandrine; C. J. van Akkooi, Alexander; Robert, Caroline; Suciu, Stefan

doi:10.1001/jamaoncol.2019.5570

Public

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

Published in JAMA Oncology • Jan 2, 2020

Authors:

Alexander M.M. Eggermont

Michal Kiciński

Christian U. Blank

Abstract

Importance: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown. Objective: To investigate the association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC 1325/KEYNOTE-054 clinical trial...

Subject

Medicine

Pembrolizumab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!